Adocia : 2024, a potentially transforming year for Adocia
>Operational cash burn down significantly - Yesterday evening, Adocia published its FY 2023 figures. Operating profit over the period was € 6m (vs € 17.3m in 2022, including a milestone payment of € 4.8m received as part of its partnership agreement in China). Underlying operating charges were down 31% to € 20.3m, driven by the reduction in R&D charges to € 14.8m (vs € 25.9m in 2022). This resulted in an operating loss of -€ 14.2m (vs -€ 12.9m previously).The cas...ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.